Physician profile
Erik P Lessmann
NPI 1225003098
$3,968.92
in general payments reported to CMS, 2019-2025
28 companies · $321 in 2025
The $321 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,057 · 2020: $539 · 2021: $792 · 2022: $566 · 2023: $276 · 2024: $418 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $958 · Education: $56.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $958.02 |
| Education | $56.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $973.23 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $405.68 | 2019-2025 | Spravato |
| Astrazeneca Pharmaceuticals LP | $334.38 | 2019-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $310.41 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $300.95 | 2019-2021 | |
| Glaxosmithkline, LLC. | $279.52 | 2019-2023 | Trelegy Ellipta |
| Abbvie INC. | $246.22 | 2021-2025 | |
| Pfizer INC. | $156.73 | 2019-2021 | |
| Lilly USA, LLC | $150.84 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Allergan, INC. | $148.13 | 2019 | |
| Mylan Specialty L.P. | $120.73 | 2019-2022 | |
| Braeburn INC. | $92.67 | 2024-2025 | Brixadi |
| Merck Sharp & Dohme LLC | $50.42 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $50.13 | 2023 | Rexulti |
| Dexcom, INC. | $49.41 | 2025 | Dexcom G6 Transmitter |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $48.08 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.93 | 2019-2021 | |
| Amgen INC. | $31.35 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.43 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.59 | 2023 | Rexulti |
| Hologic Sales and Service, LLC | $19.36 | 2021 | |
| Atland Pharmaceuticals, LLC | $18.98 | 2025 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
| Xeris Pharmaceuticals, INC. | $18.69 | 2024 | Gvoke Hypopen |
| Neurocrine Biosciences, INC. | $16.39 | 2024 | Ingrezza |
| Astellas Pharma US INC | $15.41 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.34 | 2019 | |
| Amarin Pharma, INC. | $12.22 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Lessmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.